- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1748 |
Product Name |
ADT1748-Human Anti-IGF1RxHer3 Bispecific Antibody |
Isotype |
Human IgG1-kappa-ScFv |
Clonity |
Monoclonal |
|
Alternate Names Human Anti-IGF1R mAb, Anti-IGF1R Monoclonal Antibody, IGF1R recombinant antibody, Anti-IGF1R Bispecific Antibody, Human Anti-Her3 mAb, Her3 recombinant antibody, Anti-Her3 Monoclonal Antibody, Anti-Her3 Bispecific Antibody |
|
Official Symbol |
IGF1RxHer3 |
Target 1 |
IGF1R |
Gene ID 1 |
3480 |
Target 2 |
Her3 |
Gene ID 2 |
2065 |
Species |
Human |
Drug Name |
Istiratumab |
Endotoxin |
<1EU/mg. Determined by the LAL method. |
Sterility |
0.2 μM filtered. |
Expression Host |
CHO Cells |
CAS Number |
1509928-04-4 |
Size |
1mg,5mg,50mg,100mg |
Research Area |
Cancer |
Application |
FuncS |
Purity |
>90% |
Concentration |
Batch dependent |
Buffer |
Supplied in PBS, pH 7.4,Contains no stabilizers or preservatives |
Recommended Dilution Buffer |
ABDB-1002 or PBS, pH 7.4, Contains no stabilizers or preservatives. |
Storage |
2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for one-year storage. |
Shipping Condition |
Shipped on ice packs. |
Protocol Information |
Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose-response or titration experiment. |
Note |
For Research Use Only! |
|
Reference 1. Pollak et al. (2004). Nat Rev Cancer. DOI: 10.1038/nrc1387
2. Hynes et al. (2005). Nat Rev Cancer. DOI: 10.1038/nrc1662
3. Tao et al. (2007). Cancer Res. DOI: 10.1158/0008-5472.CAN-06-4403
4. Campbell et al. (2018). Clin Cancer Res. DOI: 10.1158/1078-0432.CCR-17-0432
|
FAQ
-
+ -
What challenges exist in bispecific antibody production?
Challenges include mispairing of heavy/light chains, aggregation, low yield, and ensuring stability. Advanced engineering (e.g., CrossMab) addresses these issues.
-
+ -
How can I obtain COA of the reagent that I received?
Please contact us via email info@alphalifetech.com for detailed information about the product.
-
+ -
How do bispecific antibodies overcome tumor resistance?
By targeting two pathways (e.g., EGFR/MET), BsAbs block compensatory signaling and reduce escape mechanisms common in single-target therapies. -
+ -
What are the common off-target effects of bispecific antibodies?
Cytokine release syndrome (CRS), neurotoxicity, and on-target/off-tumor toxicity due to antigen expression in healthy tissues.